Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: Naloxone

FDA Issues Updated Prescribing Information for Opioids & Over-the-Counter Naloxone

Michele B. Kaufman, PharmD, BCGP  |  June 13, 2023

New prescribing guidance has been issued by the FDA for immediate-release and extended-release/long-acting opioids for pain management. The agency also announced multiple label updates, which include changes to the Boxed Warnings.

Filed under:AnalgesicsDrug Updates Tagged with:FDAopioidPain ManagementPain Syndrome FocusRheumprescribingPrescribing RulesU.S. Food and Drug Administration (FDA)

Canada Approves Erelzi for PsA; Plus FDA Moves to Increase Access to Naloxone

Michele B. Kaufman, PharmD, BCGP  |  February 4, 2019

Health Canada has approved Erelzi, which is biosimilar to Enbrel (etanercept), for treating psoriatic arthritis in adults…

Filed under:AnalgesicsDrug Updates Tagged with:Biologics & BiosimilarsBiosimilarsCanadaetanerceptFDAgeneric drug marketnaloxoneopioidOpioid abusePsoriatic ArthritisU.S. Food and Drug Administration (FDA)

CVS to Make Overdose Drug Naloxone Prescription-Free in Ohio

Reuters Staff  |  February 3, 2016

(Reuters)—CVS Health Corp said it would make naloxone, available without a prescription at all its pharmacies across Ohio, a state with one of the highest rates of overdose-related deaths. Naloxone is already available without a prescription in CVS Health stores in more than a dozen states. Drug overdoses increased 6.5% in 2014 from a year…

Filed under:Drug Updates Tagged with:mortality ratenaloxoneNaloxone hydrochlorideOverdose

Speak Out Rheum: How Did We Go So Wrong with Opioid Prescribing?

Richard Brasington Jr., MD, FACP, MACR  |  November 4, 2022

I have been listening to The Fighter Pilot Podcast because my fantasy career would have been to fly a jet fighter plane (not even remotely possible, given my constitution). I learned that when an aircraft accident occurs, a mishap board is convened, not to assign blame but to try to learn what went wrong and…

Filed under:AnalgesicsDrug UpdatesOpinionSpeak Out Rheum Tagged with:opioid crisisPain Syndrome FocusRheumSpeak Out Rheumatology

urfin / shutterstock.com

How to Improve Opioid Prescribing in an Outpatient Clinic

Lisa Carnago, FNP, Jenelle Hall, PharmD, & Stephanie Puryear, RMA  |  October 18, 2019

More than 72,000 Americans died from opioid overdoses in 2017, according to the National Institutes of Health.1 The impact of the opioid epidemic has affected many levels of patient care and, as a result, healthcare systems are responding to escalating death rates, new legislation and the possibility of compromised patient safety in a multitude of…

Filed under:ConditionsPain SyndromesPractice Support Tagged with:Chronic painopioid crisisprescribing

rzstudio / shutterstock.com

Prescribing Hope: The Placebo Effect Endures

Philip Seo, MD, MHS  |  June 21, 2018

“Wait. I can explain.” One could imagine this phrase coming up under many conditions in daily life. When I first became a physician, however, I would never have expected to use this phrase in my clinic. In medical school, I was taught the importance of dialogue in establishing a relationship with a patient. Statistics indicate…

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:patient communicationpatient managementplacebo

Balancing Opioid Addiction Risk with Pain Management Needs

Larry Beresford  |  February 18, 2018

SAN DIEGO—During a session at the ACR/ARHP 2017 Annual Meeting Nov. 3–8, three representatives from the federal government described several of the government’s varied national strategies and agencies that are tackling pain. All of these strategies are affected by the current national epidemic of opioid overdoses and the need for safer analgesic prescribing. But the…

Filed under:AnalgesicsDrug UpdatesEthicsLegal UpdatesMeeting Reports Tagged with:ACR/ARHP Annual Meetingopioid epidemicPain Management

Trump Panel Urges More Treatment Options to Fight Opioid Crisis

Toni Clarke  |  November 2, 2017

(Reuters)—A panel convened by U.S. President Donald Trump to tackle the opioid crisis called on Wednesday for more treatment programs, tighter prescribing guidelines and additional drug courts to help reduce overdose deaths. The commission, led by New Jersey Governor Chris Christie, said the recommendations would require funding by Congress but did not recommend an amount….

Filed under:Legislation & Advocacy Tagged with:more treatment optionsnational opioid addiction epidemicNew Jersey Governor Chris Christieopioid crisis

Many Drug Companies Fail to Conduct Timely Safety Checks on Medicines after FDA Approval

Gene Emery  |  September 22, 2017

(Reuters Health)—In the rush to approve new medicines, the U.S. Food and Drug Administration often requires drug companies to study possible side effects and alternative doses for medicines once they hit the broader market. A September 20 online analysis in the New England Journal of Medicine concludes that, in many cases, that’s not being done….

Filed under:Drug UpdatesEthics Tagged with:Dartmouth Institute for Health Policy and Clinical PracticeFDA approvalGilenya (fingolimod)Indivior's SuboxoneU.S. Food and Drug Administration

Unbudgeted: How the Opioid Crisis Is Blowing a Hole in Small-Town America’s Finances

Paula Seligson & Tim Reid  |  September 20, 2017

INDIANA, Pa./CHILLICOTHE, Ohio (Reuters)—As deaths mount in America’s opioid crisis, communities on the front lines face a hidden toll: the financial cost. Ross County, a largely rural region of 77,000 people an hour south of Columbus, Ohio, is wrestling with an explosion in opioid-related deaths—44 last year compared with 19 in 2009. The drug addiction…

Filed under:AnalgesicsDrug Updates

  • 1
  • 2
  • 3
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences